老年2型糖尿病患者中SGLT2抑制剂与GLP-1受体激动剂的比较有效性与安全性
基于Medicare数据,纳入90,094对倾向评分匹配的≥66岁2型糖尿病患者,比较SGLT2i与GLP-1RA。中位随访约6个月,SGLT2i组MACE风险相似,心衰住院风险降低,但DKA、下肢截肢和生殖器感染风险增加,急性肾损伤风险降低。
要点
- 老年T2D患者中,SGLT2i与GLP-1RA的MACE风险相似(HR 0.98)。
- SGLT2i较GLP-1RA降低心衰住院风险(HR 0.68)。
- SGLT2i增加DKA、下肢截肢和生殖器感染风险,降低急性肾损伤风险。
核心结论
- 在老年T2D患者中,SGLT2i与GLP-1RA相比MACE风险相似,心衰住院风险降低,但DKA、下肢截肢和生殖器感染风险增加。
主要发现
- 中位随访约6个月,SGLT2i组MACE风险与GLP-1RA相似(HR 0.98,95%CI 0.87-1.10;RD -0.38,95%CI -2.48-1.72)。
- SGLT2i组心衰住院风险降低(HR 0.68,95%CI 0.57-0.80;RD -3.23,95%CI -4.68至-1.77)。
- 每1000人年,SGLT2i组DKA事件多0.7例(RD 0.72,95%CI 0.02-1.41),下肢截肢多0.9例(RD 0.90,95%CI 0.10-1.70),生殖器感染多57.1例(RD 57.08,95%CI 53.45-60.70),急性肾损伤少7.1例(RD -7.05,95%CI -10.27至-3.83)。
临床怎么用
- 老年T2D患者选择SGLT2i或GLP-1RA时,需权衡心衰住院获益与DKA、下肢截肢及生殖器感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally <65 years old and mostly with cardiovascular disease. We aimed to evaluate the comparative effectiveness and safety of SGLT2i and GLP-1RA among real-world older adults. RESEARCH DESIGN AND METHODS: Using Medicare data (April 2013-December 2016), we identified 90,094 propensity score-matched (1:1) T2D patients ≥66 years old initiating SGLT2i or GLP-1RA. Primary outcomes were major adverse cardiovascular events (MACE) (i.e., myocardial infarction, stroke, or cardiovascular death) and hospitalization for heart failure (HHF). Other outcomes included diabetic ketoacidosis (DKA), genital infections, fractures, lower-limb amputations (LLA), acute kidney injury (AKI), severe urinary tract infections, and overall mortality. We estimated hazard ratios (HRs) and rate differences (RDs) per 1,000 person-years, controlling for 140 baseline covariates. RESULTS: Compared with GLP-1RA, SGLT2i initiators had similar MACE risk (HR 0.98 [95% CI 0.87, 1.10]; RD -0.38 [95% CI -2.48, 1.72]) and reduced HHF risk (HR 0.68 [95% CI 0.57, 0.80]; RD -3.23 [95% CI -4.68, -1.77]), over a median follow-up of ∼6 months. They also had 0.7 more DKA events (RD 0.72 [95% CI 0.02, 1.41]), 0.9 more LLA (RD 0.90 [95% CI 0.10, 1.70]), 57.1 more genital infections (RD 57.08 [95% CI 53.45, 60.70]), and 7.1 fewer AKI events (RD -7.05 [95% CI -10.27, -3.83]) per 1,000 person-years. CONCLUSIONS: Among older adults, those taking SGLT2i had similar MACE risk, decreased HHF risk, and increased risk of DKA, LLA, and genital infections versus those taking GLP-1RA.
引用
- Patorno E, Pawar A, Bessette LG, et al. Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care. 2021. PMID: 33495295. doi:10.2337/dc20-1464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。